Stem Cell Therapy Global Market Report 2022: Allogeneic Stem Cell Therapy; Autologous Stem Cell Therapy – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Stem Cell Therapy Global Market Report 2022: By Type, By Cell, By Application, By End-User" report has been added to ResearchAndMarkets.com's offering.

The global stem cell therapy market is expected to grow from $10.67 billion in 2021 to $11.99 billion in 2022 at a compound annual growth rate (CAGR) of 12.4%. The market is expected to reach $21.17 billion in 2026 at a CAGR of 15.3%.

The stem cell therapy market consists of the sales of stem cell therapy and related services by entities (organizations, sole traders, and partnerships) that provide stem cell therapy. Stem cell therapy, also known as regenerative medicine, promotes the repair response of diseased patient, dysfunctional or injured tissue using stem cells or their derivatives. Only goods and services traded between entities or sold to end consumers are included.

The main types of stem cell therapy are allogeneic stem cell therapy and autologous stem cell therapy. Allogeneic stem cell transplantation involves transferring stem cells from a healthy person (the donor) to the patient's body after high-intensity chemotherapy or radiation,. The various sources of cell include adult stem cells; induced pluripotent stem cells and embryonic stem cells that are used for the treatment of musculoskeletal disorders; wounds and injuries; cancer; autoimmune disorders and others. The therapies are used by hospitals and clinics.

North America was the largest region in the stem cell therapy market in 2021. Middle East is expected to be the largest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The rising prevalence of chronic diseases contributed to the growth of the stem cell therapy market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases among people, thus driving the need for stem cell therapy. According to a United Nations article, by 2030, the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic diseases is expected to reach about 60%. The rising prevalence of chronic diseases is expected to drive the stem cell therapy market.

The high cost of stem cell therapy is expected to limit the growth of the stem cell therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding.

In less wealthy countries, the lack of cost-effective therapies for chronic diseases has impacted the health conditions of the population and has led to a low average life expectancy. According to the DVCSTEM, the average cost of stem cell therapy in the USA is between $20,000 to $25,000, in Mexico, it is $33,000, in Central America, it is $30,000, and in Asia, it is $50,000, thus restraining the growth of the market.

The companies in the stem cell therapy market are increasingly investing in strategic partnerships. The strategic partnership is a mutually beneficial agreement between two companies that do not compete directly with each other.

Major players in the stem cell therapy market are

Key Topics Covered:

1. Executive Summary

2. Stem Cell Therapy Market Characteristics

3. Stem Cell Therapy Market Trends And Strategies

4. Impact Of COVID-19 On Stem Cell Therapy

5. Stem Cell Therapy Market Size And Growth

5.1. Global Stem Cell Therapy Historic Market, 2016-2021, $ Billion

5.1.1. Drivers Of The Market

5.1.2. Restraints On The Market

5.2. Global Stem Cell Therapy Forecast Market, 2021-2026F, 2031F, $ Billion

5.2.1. Drivers Of The Market

5.2.2. Restraints On the Market

6. Stem Cell Therapy Market Segmentation

6.1. Global Stem Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

6.2. Global Stem Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

6.3. Global Stem Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

6.4. Global Stem Cell Therapy Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

7. Stem Cell Therapy Market Regional And Country Analysis

7.1. Global Stem Cell Therapy Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

7.2. Global Stem Cell Therapy Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/15018b

See the original post here:
Stem Cell Therapy Global Market Report 2022: Allogeneic Stem Cell Therapy; Autologous Stem Cell Therapy - ResearchAndMarkets.com - Business Wire

Study explores the promising but still puzzling field of stem cell therapy for painful joint injuries – University of Calgary

An interdisciplinary group of researchers from across the University of Calgary campus has received two years of funding from the New Frontiers in Research Fund (NFRF) to explore novel stem cell therapies to treat challenging joint injuries that can lead to chronic pain in horses and humans.

Joint injuries involving both soft tissue and cartilage damageare common in both equine and human athletes, and poor healing can lead to chronic joint pain. Researchers are studying how stem cell therapy may help with healing.

Our equine athletes are no different (than humans), and this opportunity to put our minds together to investigate treating these challenging injuries is really exciting for both veterinary and human medicine, says Dr. Holly Sparks, DVM, PhD'19, assistant professor of large animal surgery in the Faculty of Veterinary Medicine (UCVM) and Canada Research Chair (Tier II) in Equine Regenerative Medicine.

Dr. Holly Sparks, DVM, PhD'19 a large-animal surgeon and regenerative medicine researcher is involved in a collaborative project investigating stem cell-based approaches to treating joint injuries in veterinary and human medicine.

Rahil Tarique

Were looking at utilizing regenerative-medicine approaches to treat these injuries early, in a way that will hopefully encourage more functional healing in the short term and reduce joint pain in the long term, says Sparks.

While there is a lot of promise for stem cell therapies, and no shortage of pre-clinical studies around the world, not one stem-cell therapy for humans or animals has yet been approved for use in North America.

There has been a disproportionately large amount of work done in this area, but we're no closer to an answer because there's so much variability in how people conduct this research, says Dr. Roman Krawetz, PhD, an associate professor specializing in stem cells and tissue engineering at the Cumming School of Medicine (CSM), member of the McCaig Institute for Bone and Joint Health at the CSM, and Canada Research Chair (Tier II) in Bone and Joint Stem Cell Biology.

The collaborative research team also includes Dr. Brent Edwards, PhD, associate professor in the Faculty of Kinesiology, who researches biomechanics and musculoskeletal injuries; Dr. Mike Scott, DVM, associate professor at UCVM and surgeon at Moore Equine in Calgary; and Dr. Arindom Sen, BSc'91, MSc'98, PhD'03, a professor in the Schulich School of Engineering who studies how to scale up production of stem cells. This interdisciplinary team approach is really the key to this work, and the chance to work together on this is a really exciting opportunity, says Sparks.

Dr. Roman Krawetz, PhD, an associate professor in stem cells and tissue engineering, says, while theres been a large amount of work done in stem cell therapy research, were no closer to an answer.

Supplied by Roman Krawetz

The researchers will apply the highest possible standards in consistently producing and applying stem cells for the specific application to the stifle joint, or the equine equivalent of the human knee. As well as strict quality control on how stem cells are grown, collected and manipulated, the team has the clinical knowledge to assess the outcomes.

Did this have any benefit? And if so, where? Did it regrow cartilage? Did it reduce inflammation? Did it reduce pain? says Krawetz. Whatever answer we get is going to be important to the field. If we can show that it's beneficial, great. If we show that it's not beneficial, I think that that's equally important.

The research will not only help guide veterinarians and horse-owners managing these types of injuries, but will also add significantly to the emerging body of knowledge around stem cells. While cell-based therapy shows considerable promise for treating musculoskeletal injuries like those studied here, there's still a lot to be learned about how stem cell therapy may work, says Sparks. Hopefully, we can shed some light on that with this project.

Go here to see the original:
Study explores the promising but still puzzling field of stem cell therapy for painful joint injuries - University of Calgary

How stem cell therapy can help with Alzheimers disease – Times of India

We all love to reminisce about the good old days! Memories are part of our life and everyone reflects upon the good and bad times spent. Unfortunately, with a steadily increasing incidence of Alzheimers disease globally, many are losing their memoriesin fact even losing the ability to remember basic activities that do not as such require conscious thought. What is Alzheimers disease? Alzheimers disease (AD) is one of the major causes of dementia, and as of the last decade, there are approximately 3.7 million Indians with the condition. The lack of awareness regarding the early symptoms of the disease and knowledge about the associated risks poses challenges in early diagnosis and prompt interventions. Moreover, one cannot prevent or reverse the disease process. AD begins in individuals around the age of 40-50 years when certain unwanted proteins accumulate in the brain. These protein deposits interfere with the connections in the brain and disrupt the transmission of informationconsider them roadblocks that cannot be crossed. Thus, with time and depending on the extent of protein accumulation, a patient begins to forget things and gradually fails to form a link between the sensory information gained and the required action. For example, in advanced stages, apart from being unable to recognise people (including family members) a patient might not know what to do with a toothbrush or how the lock on a door should be fastened, although these are things he/she would have been doing for years together. It is a sad sight to watch a family member deteriorate in this manner. Since such episodes affect the overall quality of life of the patient, caregivers also tend to face the burden. How can this be treated? Unfortunately, there are no medications to treat the disease. Thus, the least we can do is try to slow down the progression of the condition. To begin with, annual health check-ups must be advised to everyone over the age of 45 years, adding brain imaging where required. By this we might be able to identify AD early and initiate activities and treatment that can slow the progression, says Dr Pradeep Mahajan, Regenerative Medicine Researcher. We have stem cells and growth factors in our body, which function to control inflammation, enhance the functions of other cells, and provide a constant pool of healthy cells to regenerate lost tissues. Through cell-based therapy, we are only providing these molecules at the required location in the appropriate quantity, explains Dr Mahajan. He continues, There are several other molecules, for example, chaperones (helper proteins) and exosomes (cell-associated packets of genetic material, proteins, immune cells, etc.) that act as messenger molecules, and also help in de-tangling nerve fibres and protein deposits in the brain. These can be utilised to create a healthier environment in the brain and restore internal balance (homeostasis). With more targeted therapies being researched, it might be possible to reverse AD in the future. For now, though, regenerative medicine can be a beacon of hope for patients to help lead an independent life for as long as possible in a natural, minimally invasive manner, concludes Dr Mahajan.

Continued here:
How stem cell therapy can help with Alzheimers disease - Times of India

Gamida Cell Submits Biologics License Application for Omidubicel to the FDA – Pharmacy Times

The drug is being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant.

Gamida Cell has completed the rolling biologics license application (BLA) submission to the FDA for omidubicel for the treatment of individuals with blood cancer who need an allogenic hematopoietic stem cell transplant, the company said in a statement.1

Omidubicel is an advanced cell therapy candidate that was developed as an allogeneic hematopoietic stem cell transplant for individuals with blood cancer. It is the first stem cell transplant donor source to receive breakthrough therapy designation from the FDA.1

Additionally, it has received orphan drug designation in the European Union and the United States.1

The BLA submission marks an important milestone for both Gamida and the transplant community, as omidubicel has the potential to be the first approved advanced cell therapy product for allogeneic stem cell transplantation, Julian Adams, PhD, CEO of Gamida Cell, said in the statement.1

Completion of this BLA submission is a key inflection point in our mission to deliver a new treatment option for patients with blood cancers. We look forward to working closely with the FDA to bring this potentially important therapy to patients, Adams said.1

The FDA has 60 days to determine whether the BLA for omidubicel is acceptable for filing.1

The BLA is supported by the results of a phase 3 study published in Blood, the journal of the American Society of Hematology. The study met its primary endpoint of the median time to neutrophil engraftment in individuals with hematologic malignancies undergoing allogeneic bone marrow transplant, with patients receiving omidubicel having a median time of 12 days compared with 22 days for the umbilical cord blood graft group.1

In the key secondary endpoints of the study, approximately 55% of individuals receiving omidubicel achieved platelet engraftment by day 42 compared with approximately 35% for the comparator.1

Additionally, the rate of infection was significantly reduced, with the cumulative incidence of first grade 2 or grade 3 bacterial or invasive fungal infection for individuals randomized to omidubicel being 37% compared with 57% for the comparator.1

Hospitalization in the first 100 days after transplant was significantly reduced with a median number of days alive and out of hospital for individuals randomized to omidubicel was 61 days compared with 48 days for the comparator.1

Furthermore, 1-year post-transplant data showed sustained clinical benefits with omidubicel as demonstrated by a significant reduction in infectious complications and reduced non-relapse mortality. There was no significant increase in increases in graft-versus-host-disease rates or the relapse rate.1

The results showed that transplantation after an individual received omidubicel had fewer bacterial and viral infections and less time in the hospital, investigators said.2

Omidubicel was generally well tolerated in the phase 3 study.1

Investigators reported that the incidence of treatment-emergent serious adverse events were similar in both arms, with approximately 40% in the omidubicel group and 41% for the comparator.2

References

1. Omidubicel has orphan drug designation and breakthrough therapy designation. Gamida Cell. News release. June 2, 2022. Accessed June 3, 2022. https://investors.gamida-cell.com/news-events/press-releases/news-release-details/gamida-cell-completes-rolling-biologics-license

2. Horwitz ME, Stiff PJ, Cutler C, Brunstein C, et al; Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021;138(16):1429-1440. doi: 10.1182/blood.2021011719

Read more:
Gamida Cell Submits Biologics License Application for Omidubicel to the FDA - Pharmacy Times

Second CAR T Infusion Could Lead to New Response in B-ALL – Targeted Oncology

Several treatment options are being explored for patients who have residual disease or who relapse after CAR T-cell therapy, including a possible second infusion with the same CAR T-cell product.

Young patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) who had a suboptimal response or relapse after chimeric antigen receptor (CAR) T-cell therapy could benefi t from reinfusion, according to a retrospective review (NCT03827343).

Our study provides important insights into [second CAR T-cell infusion] outcomes, including with antigen targets beyond CD19, the study authors, including corresponding author Nirali N. Shah, MD, MHSc, of the National Cancer Institute (NCI), wrote in their report published in the Journal for ImmunoTherapy of Cancer.

Several treatment options are being explored for patients who have residual disease or who relapse after CAR T-cell therapy, including a possible second infusion with the same CAR T-cell product.

The retrospective review looked at patients with B-ALL who received a reinfusion in 1 of 3 phase 1 NCI-based clinical trials (NCT01593696, NCT02315612, NCT0344839). At fi rst CAR T-cell therapy infusion, patients received either an anti-CD19, anti-CD22, or an anti-CD19/CD22 agent. If the patients had relapse after complete remission (CR) or suboptimal response and CAR expansion, they were offered a second infusion (n = 18).

The primary aim of the review was to assess CR rates of second infusions and the rate of adverse events (AEs). Secondary goals included the characterization of CAR expansion and antigen expression as well as the impact of the intensity of lymphodepletion.

A total of 136 patients were treated across the 3 studies, but only 18 (13.2%) went on to receive a second infusion with the same CAR product. As of the time of the second infusion, the median age of patients was 19 (range, 8-31). A majority of the patients were male (88.9%), White (66.7%), and of non-Hispanic ethnicity (83.3%). As of the second infusion, 88.9% had active medullary disease, 22.2% had low marrow involvement, 66.7% had high disease burden, and 11.1% had isolated CNS disease.

Patients had received a median of 6 lines of prior therapy (range, 2-13), including prior hematopoietic stem cell transplantation (HSCT) in 77.8%, prior immunotherapy in 44.4%, and prior alternate CAR T-cell therapy in 50%.

Seven patients (38.7%) had a suboptimal response to the fi rst infusion of either partial response or stable disease, including 4 who did not have a CR from first infusion, and 11 patients (61.1%) had an antigen-positive relapse; all 18 patients had CAR expansion. The median time between the fi rst and second infusion was 116.5 days (range, 35-373), and 38.9% received therapy in between.

The second infusion was administered at the same dose for 15 patients (83.3%), at a lower dose in 2 patients (11.1%) and a higher dose in 1 (5.5%).

Seven patients (38.9%) achieved an objective marrow response to the second infusion, with 5 of these patients (71.4%) achieving a minimal residual disease (MRD) negative CR, and 6 (33.3%) had a morphologic CR.

Long-term survival with second CAR infusion was limited. All patients eventually relapsedincluding 2 with CNS disease, 3 with medullary relapse, and 1 with both medullary and extramedullary relapse and none were eligible for HSCT. The median duration of remission was 77 days (range, 54-292).

Our results suggest that diminished CAR T-cell expansion alongside antigen downregulation and loss impeded robust responses to CART2. Further exploration of the mechanisms underlying CART2 response is needed, Shah et al wrote.

Cytokine release syndrome (CRS) was observed in 83.3% of patients with fi rst infusion, including severe CRS of grade 3 or higher in 27.8%. Only 22.2% reported CRS with second infusion at a maximum severity of grade 1. Neurologic toxicity was reported with fi rst infusion in 22.2% and with second infusion in 11.1%.

Observed peripheral blood CAR T-cell expansion was higher with the fi rst infusion than the second (median, 24.05 vs 1.69 cells/mL, respectively; P = .03). Five patients (27.8%) showed no CAR expansion post second infusion. CAR expansion tended to be higher with the CD22-targeted agent than the other CAR T-cell products.

REFERENCE:

Holland EM, Molina JC, Dede K, et al. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. J Immunother Cancer. 2022;10(5):e004483. doi:10.1136/jitc-2021-004483

More here:
Second CAR T Infusion Could Lead to New Response in B-ALL - Targeted Oncology

Asymmetrex’s Kinetic Stem Cell (KSC) Counting Technology Is Featured in the Parent’s Guide to Cord Blood Foundation June Newsletter – PR Web

The Parent's Guide to Cord Blood features Asymmetrex's technology for determining the dosage of therapeutic cord blood stem cells.

BOSTON (PRWEB) June 15, 2022

The Parent's Guide to Cord Blood Foundation is well known for its excellence in advocacy and education to support parents negotiating medical treatments for their children that involve umbilical cord blood and tissues. The Parent's Guide monthly newsletter has a goal of presenting new advances in umbilical cord medical research and treatments in terms that are accessible by parents and others who are not experts. The June 2022 issue, published June 14, provides a graphical presentation of stem cell biotechnology company Asymmetrex's technology that provides the dose of therapeutic umbilical cord stem cells for the first time.

Determining the dosage of therapeutic tissue stem cells is a long-standing unmet need for all tissue stem cell therapies. More commonly mis-called adult stem cells, tissue stem cells include stem cells found in adults, children, and birth tissues like the placenta and the umbilical cord. Donor umbilical cords are currently a major focus for sourcing therapeutic tissue stem cells, which are found in both their blood (hematopoietic stem cells) and their walls (mesenchymal stem cells). Whereas the medical potential of cord mesenchymal stem cells is still under investigation, the medical efficacy of cord blood hematopoietic stem cells is well established for use in the treatment of childhood leukemias.

Cord blood treatments for children have a continuing need for a method to determine the dose of the therapeutic stem cells. The Parents Guide newsletter feature describes the two industry standards for certifying cord blood units, flow cytometry and the colony-forming unit (CFU) test. Although they are currently industry certification requirements, neither of these methods gives the stem cell dose or tells which cord blood units will be effective. By some reports, this deficiency leaves nearly 20% of treated children at risk for death.

This Junes article is the Parents Guide newsletters second feature on Asymmetrexs tissue stem cell counting technology. The first feature appeared in the January 2019 issue of the newsletter. It related the historical context, envisioned applications, and potential impact of kinetic stem cell (KSC) counting, but did not delve into how the technology worked. The latest feature uses a graphical slide format to illustrate how Asymmetrex applies computational simulation to conventional cell count data to determine the number of tissue stem cells in a sample. Asymmetrexs President and CEO James L. Sherley, M.D., Ph.D. is confident that the newsletters presentation will help both non-experts and experts to understand how Asymmetrex counts therapeutic tissue stem cells.

In the intervening 3 years, the companys KSC counting technology has advanced greatly. Just in the previous week, at the Meeting in the Millyard Summit of the Advanced Regenerative Manufacturing Institute, the company announced rapid-counting algorithms that will make stem cell counting sufficiently efficient to be performed routinely for research and medicine. CEO Sherley says that he is looking forward to a future Parents Guide newsletter reporting the use of KSC counting to identify cord blood units that work all of the time for children, instead of only about 80% of the time as now.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The companys U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems stem cell-specific quantification and stem cell expansion that have stood in the way of more-effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets kinetic stem cell (KSC) counting, the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation medicine and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute | BioFabUSA (ARMI) and the Massachusetts Biotechnology Council (MassBio).

Share article on social media or email:

Read more:
Asymmetrex's Kinetic Stem Cell (KSC) Counting Technology Is Featured in the Parent's Guide to Cord Blood Foundation June Newsletter - PR Web

I’ve Been Diagnosed with Cancer TwiceThese Are the Lessons I’ve Learned – Prevention Magazine

I expected to be diagnosed with breast cancer ever since my identical twin sister Karen started treatment for the disease seven years ago. It was only a matter of time. And while I wasnt happy to hear the words, I felt ready for the fightagain.

You see, Ive been diagnosed with cancer beforea rare, incurable blood cancer called multiple myeloma, and I wasnt expected to live more than three years. That was more than 20 years ago. Since then, Ive become a healthcare pro who shepherds patients through the system to find their cures. So when a small spot on one of my regular screenings turned out to be early stage breast cancer, I said to myself: Ive got this, its what I do. No problem.

But as I painfully re-learned with my second cancer diagnosis, cancer can be humbling. Even for a cancer expert. Even for someone who has been through this before.

When I first started battling cancer decades ago, I didnt know what I know now. But after years of research, difficult decisions and grueling treatmentsinduction therapy, chemo, stem cell transplant with my sister, maintenance therapy, relapse, infusions, side effectsI learned a fair amount about how to beat cancer. I also gained a great deal of hard-won wisdom about how the disease burdens friends and family along the way. Mine were there for me no matter how difficult the treatment, or the patient. And I could be difficult. No one knows that better than my sister.

Karen was my first call after being diagnosed with myeloma. She calmed me down when my test results were bad and bore my rage when I vented Why me? And then, when my myeloma became active and aggressive, she became my stem cell donor.

Then in 2014, eight years after giving me the life-saving gift of a stem cell transplant, Karen was diagnosed with breast cancer. Stage III. It was my turn to pay her back.

Together, we searched the internet, called every doctor and patient group, read every medical publication. Again, many decisions and years of debilitating treatments: surgery, chemo, radiation, and at least five years on therapy. Even today, she still warriors through the scans, the test results, the fear.

So how would I address my new diagnosis? I followed my tried-and true playbook, the one Id used with my sister and refined with an untold number of other patients: Google wisely, get a second opinion, find the right team, check your coverage, and always ask for the most current tests and treatments. My doctor laid out the options and encouraged me to speak with other doctors. One said low-dose tamoxifen. Another said lumpectomy, with treatment and/or radiation. Another said double mastectomy: You spent 20 years of your life trying to cure one disease; in one fell swoop you can cure this one. In the end I had all the data and science in the world. But no clear answer. The decision would be mine. The decision would be personal.

I reached out to family, to friends. My sister and I spoke endlessly about the toll of her ongoing treatment, from shortness of breath to the neuropathy that feels like shooting needles in her feet; having endured years of treatment issues myself for myeloma, I didnt know how many more I could bear, let alone more scans, more false positives, more biopsies. More restless nights and honest entries in my journal.

I spoke with friends about the burden I had put on them. On my husband, my children. Id been riding the cancer roller coaster for 25-plus years. I wanted off. And besides, having lived through a stem cell transplant, I figured double mastectomy would be easy (despite my doctors warning otherwise). Surgery on Tuesday, Moms birthday on Sunday, back to work on Monday. I put make-up on before surgery so I would look bright and healthy in a quick photo sent off to our children. This time I wouldnt burden anyone.

I was wrong. The surgery was harder than I imagined. I dont know how I could have managed without my friends to bring my favorite ginger tea, my kids to cook and walk the dog when I still couldnt hold the leash, my husband to drive me 90 minutes to each appointment, sit in with the doctor, and give me (very gentle) hugs when I needed them, and my sister to just agree it suckedno sense sugar-coating. And then there were the Zoom calls. Putting on my game face when I could barely reach for my lip gloss and concealer. Going into surgery I felt strong, in control. Coming out, I felt small. Full of doubts. Beaten up.

Sitting in her office a week later, I asked my doctor if Id made the right decision. Her response: There is no wrong answer, there is only the right answer for you.

After more than 25 years of curing my own cancer, and advising countless others how to cure theirs, heres what I know now about cancer:

My someones make me know I chose rightfor me. Thats what friends and family do. They are your sounding board to help you decide, and then they give unconditional support for that decision, and see you through no matter how hard the journey might be. Their comfort is your cure.

When facing cancer, even a cancer expert needs help.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Here is the original post:
I've Been Diagnosed with Cancer TwiceThese Are the Lessons I've Learned - Prevention Magazine

World Sickle Cell Day 2022: Know all about symptoms and treatment of the disease – Firstpost

Symptoms of the disease are usually visible at the age of 5 months and change over time. Some of the common symptoms include pain, anaemia, frequent infections, swelling of hands and feet and vision problem

Sickle-shaped cells and normal blood cells in human blood. Image courtesy: Wikimedia Commons/Dr Graham Beards

World Sickle Cell Day is marked every year on 19 June with an aim to raise awareness about sickle cell disease. Sickle Cell Disease is a group of disorders that impact haemoglobin, the molecule in red blood cells which deliver oxygen to cells throughout the body.

Individuals who live with this disease have haemoglobin S, an atypical haemoglobin molecule which distorts red blood cells into a sickle or a crescent shape. The disease is usually transmitted from parents to children.

What are the symptoms?

Symptoms of the disease are usually visible at the age of 5 months and change over time. Some of the common symptoms include pain, anaemia, frequent infections, swelling of hands and feet and vision problem.

What are the different types of Sickle Cell Disease?

If one of the parents has a problem gene, then the child will not have symptoms but will possess sickle cell trait.

What is the treatment?

The disease can be detected in an infant during the screening process of a newborn. In case, there is a family history of the Sickle Cell disease, it can even be diagnosed at the time of pregnancy.

The only way to cure it is either stem cell or a bone marrow transplant. The symptoms can also be dealt with the use of antibiotics, periodic blood transfusion, pain killers, and vaccinations.

Read all the Latest News, Trending News,Cricket News, Bollywood News, India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.

Visit link:
World Sickle Cell Day 2022: Know all about symptoms and treatment of the disease - Firstpost

NK Cell Therapy and Stem Cell Therapy Market Share, Size Global Industry Revenue, Business Growth, Demand and Applications Market Research Report to…

Global NK Cell Therapy and Stem Cell Therapy Market segments and their analysis offer a complete In-depth view of the industry to readers including stakeholders, vendors, suppliers, investors, buyers, and others too.

Global NK Cell Therapy and Stem Cell Therapy Market research report represents a In-Depth overview of the current market situation and forecast till 2029. The study perhaps a perfect mixture of qualitative and quantitative information highlighting key market developments, challenges, competition industry analysis and new opportunities available and trend within the NK Cell Therapy and Stem Cell Therapy Market. Further, this report gives NK Cell Therapy and Stem Cell Therapy Market size, recent trends, growth, share, development status, market dynamics, cost structure, and competitive landscape. The research report also includes the present market and its growth potentials in the given period of forecast. An exhaustive and professional study of the global NK Cell Therapy and Stem Cell Therapy market report has been completed by industry professionals and presented in the most particular manner to present only the details that matter the most. The report mainly focuses on the most dynamic information of the global market.

Get a sample PDF of the report https://www.marketreportsworld.com/enquiry/request-sample/21038622

About NK Cell Therapy and Stem Cell Therapy Market:-

The NK Cell Therapy and Stem Cell Therapy market has witnessed a growth from USD million to USD million from 2017 to 2022. With a CAGR of this market is estimated to reach USD million in 2029.

The report focuses on the NK Cell Therapy and Stem Cell Therapy market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19.

Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the NK Cell Therapy and Stem Cell Therapy market.

The global NK Cell Therapy and Stem Cell Therapy market size is segmented on the basis of application, end user, and region, with focus on manufacturers in different regions. The study has detailed the analysis of different factors that increase the industries growth. This study also provides the scope of different segments and applications that can potentially influence the industry in the future. Pricing analysis is covered in this report according to each type, manufacturer, regional analysis, price. NK Cell Therapy and Stem Cell Therapy Market Share report provides overview of market value structure, cost drivers, various driving factors and analyze industry atmosphere, then studies global outline of industry size, demand, application, revenue, product, region and segments. In addition, this report introduces market competition situation among the distributers and manufacturers profile, besides, market value analysis and cost chain structure are covered in this report.

Get a Sample Copy of the NK Cell Therapy and Stem Cell Therapy Market Report 2022

TOP Manufactures in NK Cell Therapy and Stem Cell Therapy Market are:

NK Cell Therapy and Stem Cell Therapy Market Forecast by regions, type and application, with sales and revenue, from 2021 to 2029. NK Cell Therapy and Stem Cell Therapy Market Share, distributors, major suppliers, changing price patterns and the supply chain of raw materials is highlighted in the report.NK Cell Therapy and Stem Cell Therapy Market Size report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.This Report Focuses on the NK Cell Therapy and Stem Cell Therapy Market manufacturers, to study the sales, value, market share and development plans in the future. It is Define, describe and forecast the NK Cell Therapy and Stem Cell Therapy Market Growth by type, application, and region to Study the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. Know significant trends and factors driving or inhibiting the NK Cell Therapy and Stem Cell Therapy Market growth opportunities in the market for stakeholders by identifying the high growth segments. Strategically it examines each submarket with respect to individual growth trend and their contribution to the NK Cell Therapy and Stem Cell Therapy Market.

Enquire before purchasing this report https://www.marketreportsworld.com/enquiry/pre-order-enquiry/21038622

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

The Global NK Cell Therapy and Stem Cell Therapy Market Trends,development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.The global NK Cell Therapy and Stem Cell Therapy Market Growth is anticipated to rise at a considerable rate during the forecast period, between 2021 and 2029. In 2021, the market was growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

To Understand How COVID-19 Impact is Covered in This Report. Request Sample copy of the report at : https://www.marketreportsworld.com/enquiry/request-covid19/21038622

NK Cell Therapy and Stem Cell Therapy Market Trend for Development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered. NK Cell Therapy and Stem Cell Therapy Market Report also mentions market share accrued by each product in the NK Cell Therapy and Stem Cell Therapy market, along with the production growth.

Regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:

North America (Covered in Chapter 6 and 13)

Europe (Covered in Chapter 7 and 13)

Asia-Pacific (Covered in Chapter 8 and 13)

Middle East and Africa (Covered in Chapter 9 and 13)

South America (Covered in Chapter 10 and 13)

Chapters Included in NK Cell Therapy and Stem Cell Therapy Market Report:

Purchase this report (Price 3450 USD for a single-user license) https://www.marketreportsworld.com/purchase/21038622

Some of the Key Questions Answered in this Report:

Detailed TOC of Global NK Cell Therapy and Stem Cell Therapy Market Development Strategy Pre and Post COVID-19, by Corporate Strategy Analysis, Landscape, Type, Application, and Leading 20 Countries

1 Market Overview 1.1 Product Definition and Market Characteristics 1.2 Global NK Cell Therapy and Stem Cell Therapy Market Size 1.3 Market Segmentation 1.4 Global Macroeconomic Analysis 1.5 SWOT Analysis

2. Market Dynamics 2.1 Market Drivers 2.2 Market Constraints and Challenges 2.3 Emerging Market Trends 2.4 Impact of COVID-19 2.4.1 Short-term Impact 2.4.2 Long-term Impact

3 Associated Industry Assessment 3.1 Supply Chain Analysis 3.2 Industry Active Participants 3.2.1 Suppliers of Raw Materials 3.2.2 Key Distributors/Retailers 3.3 Alternative Analysis 3.4 The Impact of Covid-19 From the Perspective of Industry Chain

4 Market Competitive Landscape 4.1 Industry Leading Players 4.2 Industry News 4.2.1 Key Product Launch News 4.2.2 MandA and Expansion Plans

5 Analysis of Leading Companies

6 Market Analysis and Forecast, By Product Types 6.1 Global NK Cell Therapy and Stem Cell Therapy Sales, Revenue and Market Share by Types(2017-2022) 6.1.1 Global NK Cell Therapy and Stem Cell Therapy Sales and Market Share by Types(2017-2022) 6.1.2 Global NK Cell Therapy and Stem Cell Therapy Revenue and Market Share by Types (2017-2022) 6.1.3 Global NK Cell Therapy and Stem Cell Therapy Price by Types (2017-2022) 6.2 Global NK Cell Therapy and Stem Cell Therapy Market Forecast by Types (2017-2022) 6.2.1 Global NK Cell Therapy and Stem Cell Therapy Market Forecast Sales and Market Share by Types(2022-2029) 6.2.2 Global NK Cell Therapy and Stem Cell Therapy Market Forecast Revenue and Market Share by Types(2022-2029) 6.3 Global NK Cell Therapy and Stem Cell Therapy Sales, Price and Growth Rate by Types(2017-2022)

7 Market Analysis and Forecast, By Applications 7.1 Global NK Cell Therapy and Stem Cell Therapy Sales, Revenue and Market Share by Applications(2017-2022) 7.1.1 Global NK Cell Therapy and Stem Cell Therapy Sales and Market Share by Applications(2017-2022) 7.1.2 Global NK Cell Therapy and Stem Cell Therapy Revenue and Market Share by Applications(2017-2022)

8 Market Analysis and Forecast, By Regions 8.1 Global NK Cell Therapy and Stem Cell Therapy Sales by Regions(2017-2022) 8.2 Global NK Cell Therapy and Stem Cell Therapy Market Revenue by Regions(2017-2022) 8.3 Global NK Cell Therapy and Stem Cell Therapy Market Forecast by Regions(2022-2029)

9 North America NK Cell Therapy and Stem Cell Therapy Market Analysis 9.1 Market Overview and Prospect Analysis 9.2 North America NK Cell Therapy and Stem Cell Therapy Market Sales and Growth Rate(2017-2022) 9.3 North America NK Cell Therapy and Stem Cell Therapy Market Revenue and Growth Rate(2017-2022) 9.4 North America NK Cell Therapy and Stem Cell Therapy Market Forecast 9.5 The Influence of COVID-19 on North America Market 9.6 North America NK Cell Therapy and Stem Cell Therapy Market Analysis by Country

10 Europe NK Cell Therapy and Stem Cell Therapy Market Analysis 10.1 Market Overview and Prospect Analysis 10.2 Europe NK Cell Therapy and Stem Cell Therapy Market Sales and Growth Rate(2017-2022) 10.3 Europe NK Cell Therapy and Stem Cell Therapy Market Revenue and Growth Rate(2017-2022) 10.4 Europe NK Cell Therapy and Stem Cell Therapy Market Forecast 10.5 The Influence of COVID-19 on Europe Market 10.6 Europe NK Cell Therapy and Stem Cell Therapy Market Analysis by Country

11 Asia-Pacific NK Cell Therapy and Stem Cell Therapy Market Analysis 11.1 Market Overview and Prospect Analysis 11.2 Asia-Pacific NK Cell Therapy and Stem Cell Therapy Market Sales and Growth Rate(2017-2022) 11.3 Asia-Pacific NK Cell Therapy and Stem Cell Therapy Market Revenue and Growth Rate(2017-2022) 11.4 Asia-Pacific NK Cell Therapy and Stem Cell Therapy Market Forecast 11.5 The Influence of COVID-19 on Asia Pacific Market 11.6 Asia-Pacific NK Cell Therapy and Stem Cell Therapy Market Analysis by Country

12 South America NK Cell Therapy and Stem Cell Therapy Market Analysis 12.1 Market Overview and Prospect Analysis 12.2 South America NK Cell Therapy and Stem Cell Therapy Market Sales and Growth Rate(2017-2022) 12.3 South America NK Cell Therapy and Stem Cell Therapy Market Revenue and Growth Rate(2017-2022) 12.4 South America NK Cell Therapy and Stem Cell Therapy Market Forecast 12.5 The Influence of COVID-19 on South America Market 12.6 South America NK Cell Therapy and Stem Cell Therapy Market Analysis by Country

13 Middle East and Africa NK Cell Therapy and Stem Cell Therapy Market Analysis 13.1 Market Overview and Prospect Analysis 13.2 Middle East and Africa NK Cell Therapy and Stem Cell Therapy Market Sales and Growth Rate(2017-2022) 13.3 Middle East and Africa NK Cell Therapy and Stem Cell Therapy Market Revenue and Growth Rate(2017-2022) 13.4 Middle East and Africa NK Cell Therapy and Stem Cell Therapy Market Forecast 13.5 The Influence of COVID-19 on Middle East and Africa Market 13.6 Middle East and Africa NK Cell Therapy and Stem Cell Therapy Market Analysis by Country

14 Conclusions and Recommendations 14.1 Key Market Findings and Prospects 14.2 Advice for Investors

15 Appendix 15.1 Methodology 15.2 Research Data Source

Continued

Browse complete table of contents at https://www.marketreportsworld.com/TOC/21038622

About Us:

Market Reports Worldis the Credible Source for Gaining the Market Reports that will Provide you with the Lead Your Business Needs. Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.

Contact Us:

Market Reports World

Phone:US : +(1) 424 253 0946 UK : +(44) 203 239 8187

Email:[emailprotected] Web:https://www.marketreportsworld.com

Other Reports Here:

Amino Silicone Oil Market Share, Size, Growth Industry Trends, Global Competitors Strategy, Segments, Regional Analysis, Review, Key Players Profile, Statistics and Growth to 2028 Analysis

Foundry Binder Market Size, Growth 2022 Global Industry Updates, Leading Players, Future Business Prospects, Forthcoming Developments and Future Investments by Forecast to 2028

Cooling Fan Market Share, Size Global Industry Revenue, Business Growth, Demand and Applications Market Research Report to 2028

Pharmaceutical Grade Phycocyanin Market Share 2022 Global Future Regional Trend, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2028

LED Retrofit Market Share, Size 2022 : Global Key Findings, Industry Demand, Growth Status, Regional Analysis, Key Players Profiles, Future Prospects and Forecast to 2028

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit NK Cell Therapy and Stem Cell Therapy Market Share, Size Global Industry Revenue, Business Growth, Demand and Applications Market Research Report to 2029

Read more here:
NK Cell Therapy and Stem Cell Therapy Market Share, Size Global Industry Revenue, Business Growth, Demand and Applications Market Research Report to...

Alopecia: Are there any new treatments on the horizon? – Pharmaceutical Technology

Last Friday, the US FDA decided to keep the popular anti-baldness drug finasteride on the market, but is now requiring its makers to add suicidal ideation to a list of potential side effects.

Relatedly, on 13 June, the FDA also approved Eli Lillys and Incytes Olumiant (baricitinib), the first treatment for alopecia areata, another form of baldness, which also has a positive Committee for Medicinal Products for Human Use (CHMP) recommendation for an EMA approval. Alopecia areata is an autoimmune disorder when the bodys immune cells attack the hair follicles, while androgenic alopecia is a genetically determined pattern of hair loss.

These recent regulatory actions have brought attention to the hair loss space which has ample demand for treatments, but relatively few unique assets in development.

Though we are seeing new developments in the treatment of androgenetic alopecia (AGA) emerge in recent years, such as low dose oral minoxidil and bicalutamide, effective management remains challenging, writes Dr Dmitri Wall, consultant dermatologist at Hair Restoration Blackrock in Dublin, via email.

Marketed by Organon, a Merck spinoff, finasteride sold as Propecia had global sales of $292 million in 2005, as per GlobalData. The first generic was introduced in 2006. The FDAs most recent action came in response to a petition launched by a non-profit group called the Post-Finasteride Syndrome Foundation.

In 1988, the FDA approved minoxidil, a 2% topical solution then marketed by the company Upjohn under names such as Rogaine, for male use, before receiving approval for women in 1992. Several years later, a stronger 5% formula was approved for men in 1997, with a female version receiving the green light in 2014. Upjohn merged with the Swedish company Pharmacia AB in 1995, before being acquired by Pfizer in 2002.

Almost a decade after the initial approval of minoxidil, the FDA authorized the use of 1mg finasteride tablets in 1997, a dihydrotestosterone (DHT) blocker.

Finasteride is currently not approved for use by women and is contraindicated for pregnancy, as based on Propecias FDA label. However, there are cases of advised off-label use amongst postmenopausal and occasionally premenopausal women, says Eva Proudman, consultant trichologist and chair of the Institute of Trichologists.

Finasteride and minoxidil are used with roughly 80% of patients in Proudmans estimates, seeing a very positive result. While side effects do exist, she says her practice always discusses any safety concerns.

This isnt the first time finasterides potential side effects have received attention. In 2012, the FDA requested an update of the drugs label to include mention of risks of potential sexual dysfunction. According to Mercks label for Propecia, decreased libido and erectile dysfunction were reported in 1.8% and 1.3% of 945 treated subjects respectively. The latest suicidal ideation warning comes after internal records from Merck showed the company was aware of over 200 cases of depression since 2009, as described in a Reuters exclusive last February.

At the same time, it is important to note that hair loss can prove as a very emotional process for some and there are more factors surrounding potential depression or suicidal ideation than just in case of finasteride use, says Proudman. As such, understanding what these treatments can potentially do is needed, she adds.

Moreover, some studies show that the topical treatment minoxidil is also potentially not for everyone. In a Pfizer-sponsored one-year observational study of minoxidils 5% solution from 2004, the treatment shrunk the targeted hair-loss area in 62% of subjects, but it remained unchanged in 35.1%. In the same study, 15.9% of the subjects rated the treatment as very effective, but 20.6% found it only moderately effective and 15.7% found no effects. The topical solution is intended for use in the crown and is not aimed for the treatment of frontal baldness or a receding hairline, as based on Rogaines label.

Dutasteride, another DHT blocker sold by GSK under the name Avodart, has also displayed efficacy in reducing hair loss. But the treatment has not yet been approved by the FDA for the treatment of androgenic alopecia, despite off label use.

Outside of these two established treatments, cosmetic procedures such as scalp micropigmentation, scalp reduction or hair transplantation are becoming increasingly prominent. We continue to await the delivery of safe and effective stem-cell therapy that has promised much, while limited evidence regarding adjuvant therapies such as platelet rich plasma (PRP) and low-level laser therapy (LLLT) is yet to convincingly prove their benefit, says Wall, who is also an assistant professor at the Charles Institute of Dermatology at University College Dublin.

According to GlobalDatas Pharma Intelligence Centre, there are currently 20 assets in development for androgenic alopecia. This ranges from minoxidil that is in pre-registration in Taiwan, to IVL3001, a month-lasting injection of finasteride made by the South Korean company Inventage Lab, and treatments previously unused within the space such as Cosmo Pharmaceuticals topical solution Breezula (clascosterone).

Other approaches include antiandrogens such as GT-20029 or KX-826 (pyrilutamide), developed by the Chinese pharma company Kintor Pharmaceuticals. Pyrilutamide is currently in two Phase II studies, with one for male androgenic alopecia subjects in the US, and the other for female subjects in China.

At the same time, Proudman stresses the need for efficacious products, rather than those with promises. In June 2021, the Swedish company Follicum announced its discontinuing a Phase IIa hair loss treatment FOL-005 after an independent review led to revised data showing no significant improvement.

In this sense, Proudman says it is likely that upcoming treatments will be similar to those in the available armamentarium.

"Even with the emergence of novel therapies, it remains most likely that optimal, sustained responses will require combination therapy that should be chosen after consideration of individual factors," notes Wall.

Quality Assurance and Research Tools for Pharmaceutical Developers

Global Contract Services for Pre-Clinical Studies

Contract Pharmaceutical Development Services and Commercial Manufacturing in Advanced Softgel Technologies

More:
Alopecia: Are there any new treatments on the horizon? - Pharmaceutical Technology